1. Home
  2. EDUC vs LNAI Comparison

EDUC vs LNAI Comparison

Compare EDUC & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Educational Development Corporation

EDUC

Educational Development Corporation

HOLD

Current Price

$1.35

Market Cap

10.7M

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$0.32

Market Cap

11.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EDUC
LNAI
Founded
1965
N/A
Country
United States
United States
Employees
N/A
29
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7M
11.9M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
EDUC
LNAI
Price
$1.35
$0.32
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
11.7K
38.8M
Earning Date
05-18-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.63
N/A
Revenue
$34,191,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$0.15
52 Week High
$1.84
$1.66

Technical Indicators

Market Signals
Indicator
EDUC
LNAI
Relative Strength Index (RSI) 55.32 43.28
Support Level $1.35 $0.15
Resistance Level $1.37 $0.99
Average True Range (ATR) 0.06 0.10
MACD 0.01 0.00
Stochastic Oscillator 81.20 6.15

Price Performance

Historical Comparison
EDUC
LNAI

About EDUC Educational Development Corporation

Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: